Vitae

Home > Vitae

Andy Yeh Alpha

Virtual net portfolio value:$4,971,148

Net overall return per annum:45.24%

Laura Hermes

Virtual net portfolio value:$1,937,303

Net overall return per annum:33.07%

Chanel Holden

Virtual net portfolio value:$1,819,336

Net overall return per annum:31.68%

Charlene Vos

Virtual net portfolio value:$1,727,166

Net overall return per annum:30.38%

Monica McNeil

Virtual net portfolio value:$1,621,402

Net overall return per annum:28.99%

Daisy Harvey

Virtual net portfolio value:$1,602,568

Net overall return per annum:28.73%

Olivia London

Virtual net portfolio value:$1,576,799

Net overall return per annum:28.36%

Dan Rochefort

Virtual net portfolio value:$1,563,625

Net overall return per annum:28.06%

Apple Boston

Virtual net portfolio value:$1,559,366

Net overall return per annum:27.99%

Jacob Miramar

Virtual net portfolio value:$1,547,838

Net overall return per annum:27.98%

Peter Prince

Virtual net portfolio value:$1,558,902

Net overall return per annum:27.97%

Becky Berkman

Virtual net portfolio value:$1,544,745

Net overall return per annum:27.88%

Rose Prince

Virtual net portfolio value:$1,544,394

Net overall return per annum:27.80%

Fiona Sydney

Virtual net portfolio value:$1,541,139

Net overall return per annum:27.73%

John Fourier

Virtual net portfolio value:$1,538,745

Net overall return per annum:27.72%

Jonah Whanau

Virtual net portfolio value:$1,517,525

Net overall return per annum:27.34%

James Campbell

Virtual net portfolio value:$1,505,573

Net overall return per annum:27.33%

Joseph Corr

Virtual net portfolio value:$1,465,707

Net overall return per annum:26.60%

Blog+More
Amazon follows Apple to become the second U.S. public corporation to hit $1 trillion stock market valuation.
Dan Rochefort

2018-09-03 09:31:00 Monday ET

Amazon follows Apple to become the second U.S. public corporation to hit $1 trillion stock market valuation.

Amazon follows Apple to become the second American public corporation to hit $1 trillion stock market valuation. Amazon's founder and chairman Jeff Bezo

+See More
Thomas Piketty empirically shows that the top 1% cohort rakes in 20%+ of U.S. national income.
Daisy Harvey

2018-09-01 07:34:00 Saturday ET

Thomas Piketty empirically shows that the top 1% cohort rakes in 20%+ of U.S. national income.

As the French economist who studies global economic inequality in his recent book *Capital in the New Century*, Thomas Piketty co-authors with John Bates Cl

+See More
Clayton Christensen defines the core dilemma of corporate innovation with sustainable and disruptive advances.
Daisy Harvey

2020-04-17 07:23:00 Friday ET

Clayton Christensen defines the core dilemma of corporate innovation with sustainable and disruptive advances.

Clayton Christensen defines and delves into the core dilemma of corporate innovation with sustainable and disruptive advances. Clayton Christensen (2000)

+See More
Elizabeth Warren warns of Trump financial reforms that shake up the 5 key pillars of bank regulation.
Dan Rochefort

2017-11-19 08:37:00 Sunday ET

Elizabeth Warren warns of Trump financial reforms that shake up the 5 key pillars of bank regulation.

In 2000, a former law professor at Harvard proposed establishing the Financial Product Safety Commission in order to protect consumer rights in the provisio

+See More
President Trump signs an executive order to freeze federal employee pay in early-2019.
Rose Prince

2019-01-06 08:39:00 Sunday ET

President Trump signs an executive order to freeze federal employee pay in early-2019.

President Trump signs an executive order to freeze federal employee pay in early-2019. Federal employees face furlough or work without pay due to the govern

+See More
The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.
Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More